Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$10.29 ▼ -0.36
(-3.38%)
MKT CAP: $647.0M • VOL: 1.03M
52W L $9 52W H $26
DBVT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $5.6M | $4.2M | $15.7M |
| YoY Revenue Growth % | +35.8% | -73.6% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$147.1M | -$116.6M | -$76.4M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$146.9M | -$113.9M | -$72.7M |
| EBITDA (Normalized) | -$146.6M | -$114.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$121.2M | -$104.5M | -$79.7M |
| Capital Expenditures (CapEx) | $532.0K | $2.3M | — |
| Free Cash Flow (FCF) | -$121.7M | -$106.8M | -$79.7M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $194.2M | $32.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $168.8M | $27.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DBVT.